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Summary
The vacuolar protein sorting machinery regulates mul-
tivesicular body biogenesis and is selectively recruited
by enveloped viruses to support budding. Here we re-
port the crystal structure of the human ESCRT-III pro-
tein CHMP3 at 2.8 A˚ resolution. The core structure of
CHMP3 folds into a flat helical arrangement that assem-
bles into a lattice, mainly via two different dimerization
modes, and unilaterally exposes a highly basic surface.
The C terminus, the target for Vps4-induced ESCRTdis-
assembly, extends from the opposite side of the mem-
brane targeting region. Mutations within the basic and
dimerization regions hinder bilayer interaction in vivo
and reverse the dominant-negative effect of a truncated
CHMP3 fusion protein on HIV-1 budding. Thus, the final
steps in the budding process may include CHMP pro-
tein polymerization and lattice formation on mem-
branes by employing different bilayer-recognizing sur-
faces, a function shared by all CHMP family members.
Introduction
Complex and conserved protein machineries largely en-
coded by class E vacuolar protein sorting (VPS) genes
regulate the sorting and trafficking of proteins into multi-
vesicular bodies (MVB). This involves the delivery of
cargo such as epidermal growth factor receptor (EGF)
(Gordon et al., 1978) into small vesicles that are formed
at the endosomal membrane and are released into the
endosome, giving rise to MVB. MVB structures then
fuse with late endosomes and lysosomes, thus deliver-
ing their cargo for degradation (Futter et al., 1996).
Tagged by ubiquitin, protein cargo is first recognized
by the HRS-STAM complex that recruits ESCRT-I to the
endosomal membrane (Bache et al., 2003; Katzmann
et al., 2001, 2003). This in turn activates assembly of
ESCRT-II and -III complexes (Babst et al., 2002a,
2002b; Gruenberg and Stenmark, 2004; Katzmann et al.,
2002), which have been implicated in protein sorting, ves-
icle formation, and budding of vesicles from the endoso-
mal membrane (Babst et al., 2002a, 2002b; Gruenberg
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contains six members in yeast, forming three distinct
subcomplexes, namely Snf7p/Vps20p (CHMP4/6),
Vps2p/Vps24p (CHMP2/3), and Did2p/Vps60p (CHMP1/
5) (Babst et al., 2002a). Similarly, human cells contain
ten ESCRT-III proteins, the CHMP family (CHMP1–6;
charged multivesicular body protein), with two isoforms
of CHMP1 and 2 and three isoforms of CHMP4 (Howard
et al., 2001; Martin-Serrano et al., 2003; von Schwedler
et al., 2003). Although the exact sequence of recruitment
is unknown, most molecular interactions between CHMP
members have been described. CHMP6 is N-myristoy-
lated, recruited by ESCRT-II, and interacts with CHMP4
members, which in turn bind CHMP3. CHMP3 recognizes
the phospholipid PtdIns(3,5)P2 (Whitley et al., 2003),
which has been implicated in vacuole size control in yeast
(Rudge et al., 2004). Furthermore, CHMP3 interacts with
CHMP2 members (Morita and Sundquist, 2004) and
AMSH, thus linking CHMP3 to the HRS-STAM complex
(McCullough et al., 2006).
Based on the network of interactions between CHMP
family members, it has been suggested that upon inter-
action with cellular membranes, single proteins and/or
subcomplexes assemble into a distinct protein network
that regulates late steps in budding (Babst et al., 2002a;
Katzmann et al., 2002; Lin et al., 2005; Morita and Sund-
quist, 2004). Membrane targeting of CHMP proteins in
turn recruits the AAA-type ATPase Vps4, which disas-
sembles and recycles ESCRT complexes (Babst et al.,
1998, 2002a; Fujita et al., 2003; Lin et al., 2005; Morita
and Sundquist, 2004; Strack et al., 2003; von Schwedler
et al., 2003; Yoshimori et al., 2000).
MVB formation involves vesicle budding away from
the cytosol and is thus morphologically similar to the
budding mechanism of enveloped viruses. HIV-1, for ex-
ample, enters the MVB pathway via Gag p6 late domain
interactions with ESCRT-I Tsg101 and Alix/AIP1, which
helps to recruit downstream factors such as ESCRT-III
members and Vps4 (Garrus et al., 2001; Martin-Serrano
et al., 2003; Strack et al., 2003; von Schwedler et al.,
2003). Notably, expression of a number of ESCRT-III
CHMP isoforms, including CHMP3, can exert a domi-
nant-negative effect on retrovirus budding. Its induced
phenotype is similar to the one observed for expression
of inactive Vps4, indicating that ESCRT-III is absolutely
required for retrovirus release and most likely acts
upon the final steps of the budding process (Martin-Ser-
rano et al., 2003; Strack et al., 2003; von Schwedler et al.,
2003). Here we report the crystal structure of a CHMP
protein family member and relate its structure to its pro-
posed role in the membrane fission process that leads to
release of endosomal vesicles and enveloped viruses
from cellular membranes.
Results
CHMP3 Dimerizes upon Removal of a C-Terminal
Region In Vitro
Chemical crosslinking and gel filtration chromatography
reveal that recombinant human full-length CHMP3
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822(residues 1–222) and an N- and C-terminal truncated
form of CHMP3, containing residues 9–183 (CHMP3[9–
183]), are both monomeric in solution. No significant
bands corresponding to potential dimeric forms of
CHMP3, which should migrate at w60 kDa (CHMP3-
WT) and w40 kDa (CHMP3[9–183]), are observed upon
crosslinking with ethylene glycol bis-succinimidylsucci-
nate (EGS) (Figure 1A, lanes 1–6). However, CHMP3,
containing residues 9–164 (CHMP3[9–164]), lacking
most of the acidic region (residues 141–222), forms di-
mers under the same crosslinking conditions as indi-
cated by the appearance of a new band migrating at
w35 kDa (the monomer migrates at w17 kDa)
(Figure 1A, lanes 7–9). In addition, dynamic light scatter-
ing yielded hydrodynamic particle radius values ofw2.5
nm for both CHMP3 and CHMP3(9–183), and w3.8 nm
for dimeric CHMP3(9–164). These results indicate that
CHMP3 is a monomer in solution and removal of part
of the C terminus leads to spontaneous dimerization.
The Crystal Structure of CHMP3
To gain insight into the structural requirements for
CHMP protein function including membrane interaction,
we crystallized CHMP3(9–183). The structure was deter-
mined from a selenomethionine-containing crystal using
the single wavelength anomalous dispersion method
and diffraction data to 2.8 A˚ resolution, which resulted
in an interpretable electron density map (Figure 2A).
The P1 crystal unit cell contains four monomers
(Figure 2B) forming two identical antiparallel dimers,
with dimensions of 88 3 43 3 35 A˚ (Figure 2C). The
CHMP3(9–183) monomer folds into a helical arrange-
ment, which is dominated by a 70 A˚ long helical hairpin
that together with two short helices forms a four-helical
bundle (Figure 2B). A fifth helical segment is connected
to the core via a 20 residue long largely disordered linker
and is positioned perpendicularly to the core (Figures 2C
and 2D). This arrangement generates a flat molecule
with the C-terminal ends emanating from one side of
the structure (Figure 2D).
Dimerization is mainly mediated by helix 2-helix 2 in-
teractions, with some contributions from helices 1 and
5. Although the flat interface covers an extensive total
surface of 3476 A˚2, approximately half of the residues
at the interface are not in close enough contact (>3.5
A˚) to mediate direct interactions (Figure 3A). Dimeriza-
tion involves mostly van der Waals contacts and a few
polar interactions such as a salt bridge between E42
OE1 and R99* NH2 (*, second monomer) and hydrogen
bonds between the carbonyl of Q38 and R99* NH1 as
well as N85 OD1 and N85* ND2 (Figure 3C). To test
whether this dimerization interface exists in solution,
centrally located residues were mutated in CHMP3(9–
164) (mutant 1, M1, Y78 to R, A79 to E), as CHMP3(9–
183) does not dimerize in solution (Figure 1A). Purifica-
tion of M1 on gel filtration reveals two overlapping
peaks, a minor one at 10.1 ml and a major peak at 11.2
ml, respectively. Chemical crosslinking shows that the
11.2 ml peak is monomeric, as M1 cannot be efficiently
crosslinked and remains monomeric (Figure 1B, lanes
4–6), while the 10.1 ml peak is efficiently crosslinked to
a dimeric form migrating at w37 kDa (Figure 1B, lanes
1–3). Extension of the changes in the interface to gener-
ate a mutant M1.2 (Y78R, A79E, A82Y; Figure 3A) re-vealed an identical monomer-dimer mixture as shown
for M1 (data not shown). These results suggested that
this dimerization interface (dimer 1) is used in vitro but
mutation of central residues is not sufficient to com-
pletely prevent dimerization. Because the crystal pack-
ing presents a second dimerization mode via the tips
of the helical hairpins (Figure 2E, dimer 2), we mutated
residues within this interface (Figure 3B), which is
formed by a small hydrophobic core (V59, V62, L63)
that is capped by polar contacts on either side (E40
OE1-K54 NZ, Q56 OE1-E66 OE1) (Figures 3D). Purifica-
tion of M2 (K54S, Q56N, V59E, V62D, L63E) by gel filtra-
tion revealed two overlapping peaks, a minor one eluting
atw10.4 ml and a major one eluting atw11.4 ml, similar
to the elution profile of M1. Chemical crosslinking of
samples from both peaks identified that peak 1 contains
a dimeric form of M2, as it can be crosslinked to a new
Figure 1. Removal of C-Terminal Sequences Activates the Transi-
tion from a Monomeric to a Dimeric Form of CHMP3
(A) Chemical crosslinking of recombinant CHMP3 wild-type (lanes
1–3), CHMP3(9–183) (lanes 4–6), and CHMP3(9–164) (lanes 7–9) (no
EGS, lanes 1, 4, and 7; 0.5 mM EGS, lanes 2, 5, and 8; 5 mM EGS,
lanes 3, 6, and 9); complete dimerization is only observed in the
case of CHMP3(9–164). Crosslinking of CHMP3 and CHMP3(9–
183) reveals faint bands corresponding to the size of dimers (*)
and internal crosslinking of the monomeric form as evident from
a second monomer band migrating slightly faster on SDS-PAGE.
(B) Chemical crosslinking of the mutant M1 (Y78R, A79E) reveals
monomers and dimers. Lanes 1–3 show crosslinking of a sample
from the minor 10.1 ml gel filtration peak, and lanes 4–6 from the ma-
jor 11.2 ml gel filtration peak.
(C) Chemical crosslinking of mutant M2 (K54S, Q56N, V59E, V62D,
L63D) shows monomers in the major 11.4 ml gel filtration peak (lanes
1–3) and dimer formation in the minor 10.4 ml gel filtration peak
(lanes 4–6).
(D) Chemical crosslinking of M3 (a combination of M1 and M2) re-
veals only monomeric CHMP3(9–164) (lanes 1–3).
In (B)–(D), lanes 1 and 4, no EGS; lanes 2 and 5, 1 mM EGS; and lanes
3 and 6, 5 mM EGS.
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(A) Stereo image of the experimental electron density map obtained
from SAD phases and noncrystallographic symmetry averaging
showing a central fragment of the long helical hairpin as an all-
atom model.
(B) Crystal structure of CHMP3(9–183). Ribbon representation of the
CHMP3(9–183) monomer that is dominated by a 70 A˚ long helical
hairpin that together with the short helices 3 and 4 forms a four-he-
lical bundle. A fifth helix, connected via a long disordered loop (res-
idues w140–161), packs perpendicular to the helical bundle struc-
ture and its orientation is determined by dimerization contacts.
Secondary structure elements and residue numbers are indicated.
The disordered loop region connecting helices 4 and 5 is drawn as
a dotted line.
(C) Ribbon representation of the CHMP3(9–183) dimer (dimer 1) in
yellow and orange. Antiparallel dimerization is mediated mainly by
interactions via the long helical hairpin and additional contribution
of helix 5. Dimerization generates a flat assembly of 883 433 35 A˚.
(D) Ribbon diagram of dimer 1 viewed from the side. This shows the
perpendicular packing of helix 5 against the tip of the helical hairpin
and the orientation of the C termini toward one side of the flat mol-
ecule.
(E) The crystal lattice reveals a dimerization mode via the tips of the
helical hairpins (dimer 2). Such dimer formation in vitro was con-
firmed by mutagenesis analyses (M2).band migrating at w37 kDa on SDS-PAGE (Figure 1C,
lanes 4–6), while the 11.4 ml peak contained only the mo-
nomeric form that did not crosslink (Figure 1C, lanes 1–
3). When we mutated both potential dimerization re-
gions simultaneously, the resulting M3 mutant protein
eluted as a single peak (11.9 ml) from a gel filtration col-
umn that remained monomeric upon chemical cross-
linking (Figure 1D). This indicates that CHMP3(9–164) di-
merizes in solution, most likely by employing both
dimerization interfaces.
It is thus conceivable that the crystallization condi-
tions induced the formation of dimers by dislodging
the C-terminal acidic region of monomeric CHMP3(9–
183) from its N-terminal core. This mechanism is
Figure 3. Close-Up of the CHMP3 Dimerization Interface
(A) Surface representation of the CHMP3 monomer. Residues in
close contact (<3.5 A˚) within the dimer 1 interface are labeled in yel-
low and those buried but further apart than 3.5 A˚ are shown in or-
ange.
(B) Surface representation of the CHMP3 monomer rotated by 180º
along the y axis showing the dimer 2 interface. Same color coding as
in (A).
(C) Close-up of the dimer 1 interface of one half related by a 2-fold
axis. The dimer interface occupies a total surface of 3476 A˚2.
(D) Close-up of the dimer 2 interface. Residues in close contact (<3.5
A˚) are drawn with side chains and polar interactions are indicated by
dashed lines in (C) and (D). The dimer interface occupies a total sur-
face of 840 A˚2.
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(A) Structure-based sequence alignment of human CHMP3 (GenBank accession number NM_016079), CHMP1A (AF281063), CHMP2A
(NM_014453), CHMP4A (Q9BY43), CHMP5 (NM_016410), and CHMP6 (NM_024591). Residues implicated in CHMP3 dimerization are indicated
by red asterisks (dimer 1). Residues involved in further observed dimer-dimer interactions are marked by green triangles (convex dimer;
Figure 5D), blue triangles (concave dimer; Figure 5D) and black triangles (dimer 2; Figures 3D and 5D). The N- and C-terminal ends of the con-
struct crystallized are indicated by arrows. Secondary structure elements are shown and the disordered region connecting helices 4 and 5 is
drawn as a dashed line.
(B) Surface representation of the proposed membrane targeting surface of homodimeric CHMP proteins composed of helices 1 and 2 (the re-
maining C-terminal part of the structure including residues 101–183, which probably does not contribute to the membrane binding surface, was
omitted for clarity). CHMP protein sequences were modeled onto the CHMP3 structure based on the sequence alignment shown in (A). Basic
residues are shown in blue, acidic residues in red, polar residues in yellow, and hydrophobic residues in green. One basic residue exposed
in the center of helix 1 and the strictly conserved basic residue corresponding to CHMP3 K49 are indicated for orientation.indirectly supported by the high flexibility at the C-termi-
nal region of CHMP3, including helix 5 (B factors > 90 A˚2)
in all four monomers of the P1 cell.
CHMP Protein Sequence Conservation and Potential
Heterodimerization
Although CHMP proteins from the six subgroups display
only limited sequence conservation (Figure 4A), the cor-
responding orthologs from different species are highly
conserved, including human CHMP3 and yeast Vps24
(Whitley et al., 2003). Biochemical studies have shownthat yeast Vps24p and Vps2p (CHMP3/CHMP2) form
a subcomplex (Babst et al., 2002a), a result consistent
with the observed interaction of human CHMP3 and
CHMP2A/B (Martin-Serrano et al., 2003; von Schwedler
et al., 2003). Sequence comparisons reveal CHMP2A as
the closest homolog of CHMP3 (with 23.9% identity,
compared to 11%–17% with all other CHMPs). Because
most of the residues involved in both dimerization
modes are conserved between CHMP3 and CHMP2A
(Figure 4), heterodimer formation (Babst et al., 2002a;
Martin-Serrano et al., 2003; von Schwedler et al., 2003)
Crystal Structure of CHMP3
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CHMP3(9–183) Reveal a Flat Membrane Tar-
geting Surface (Electrostatic Potential <220
kBT in Red and >+20 kBT in Blue)
(A) One surface of the flat CHMP3 dimer 1 car-
ries an extensive basic surface charge which
is involved in bilayer interaction via electro-
static forces. Basic residues conserved
among CHMP3 homologs are indicated. The
total surface exposed for membrane interac-
tion isw2700 A˚2 per monomer. Note that mu-
tagenesis of residues R24, K25, R28, R32,
and R35 abolishes membrane targeting and
thus inhibits the dominant-negative effect of
CHMP3 on HIV-1 budding.
(B) Dimer 1 viewed from the side showing he-
lix 5 and the C-terminal end (arrow) pointing
away from the surface opposite the proposed
membrane targeting surface (same orienta-
tion as in Figure 2D).
(C) View of the surface opposite the membrane
targeting surface, which is less positively
charged. The direction of the C-terminal ends (arrow) indicates their optimal position to interact with the AAA-type ATPase Vps4. Thus, the
Vps4 binding site accessibility on CHMP3 within a potential CHMP protein lattice allows disassembly (Babst et al., 1998). Residues indicating
the C-terminal end and some basic residues are labeled (same orientation as in Figure 2C).
(D) The CHMP3(9–183) dimer forms a lattice in the crystal which exposes the proposed membrane interaction surface on one side. Six dimers of
the lattice are shown, which form three types of dimer-dimer interactions, exposing a convex (1), a concave (2), and a flat (3; or dimer 2) basic
surface (see arrow).could involve similar interactions as observed for the
CHMP3 homodimerization in vitro (Figures 3C and 3D).
Electrostatic Potential Map of CHMP3 Reveals
a Membrane Targeting Surface
The electrostatic potential map of CHMP3(9–183) re-
veals that one side of the flat molecule, composed of
the long helical hairpin (helices 1 and 2), displays an ex-
tensive basic surface charge covering a total surface of
w5500 A˚2, which we suggest as constituting the mem-
brane interaction surface (Figure 5A). Notably, most of
the exposed basic residues are conserved between hu-
man and yeast CHMP3 (Whitley et al., 2003), but not
among mammalian CHMP family members (Figure 4A).
The diversity of the membrane targeting properties of
mammalian CHMP family members becomes obvious
when the residues are mapped onto models of CHMP
proteins based on the dimeric CHMP3 structure (Fig-
ure 2C) and the sequence alignment (Figure 4A). The dif-
ferences in surface charge of the proposed membrane
targeting side of CHMP1A, 2A, 4A, 5, and 6 imply indi-
rectly that CHMP protein membrane interactions may
have slightly different requirements for bilayer lipid con-
tents (Figure 4B).
In contrast, the opposite site of the molecule from
which the C termini emanate (Figure 5B) displays
a smaller amount of basic charges, of which much fewer
are conserved (Figures 5C). This arrangement places the
acidic C terminus in an ideal position to recruit the
ATPase Vps4 (Figures 2D and 5C), which has been pro-
posed to disassemble CHMP protein lattices on mem-
branes initiated by interactions of the Vps4 MIT domain
with the C-terminal acidic tails of CHMP proteins (Fujita
et al., 2004; Lin et al., 2005; Scott et al., 2005a, 2005b).
The extensive basic region becomes even more evident
upon calculation of the electrostatic potential of the
CHMP3 lattice, suggesting how CHMP3 may form
a membrane-associated network (Figure 5D).Effects of Basic Residues and of the Dimerization
Interfaces on HIV-1 Budding
A number of studies have shown that the expression of
CHMP proteins either as fusion proteins or as C-termi-
nally truncated forms exerts a dominant-negative effect
on virus budding in HIV-1-producing cells, or induce an
aberrant cellular class E compartment similar to that in-
duced by Vps4 active site mutants (Babst et al., 1998;
Lin et al., 2005; Martin-Serrano et al., 2003; Strack
et al., 2003; von Schwedler et al., 2003; Whitley et al.,
2003). Here we show that expression of CHMP3 resi-
dues 1–150 fused to GFP-PK in 293T cells cotransfected
with HIV-1 proviral DNA has a dominant-negative effect
and completely blocks HIV-1 virus production, as mea-
sured by the release of the HIV-1 CA protein (Figure 6A,
WT, lane 2). The substitution of three basic residues in
GFP-PK-CHMP3(1–150) (M4, R24S, K25A, R28S; Fig-
ure 5A) profoundly diminishes the dominant-negative ef-
fect, allowing HIV-1 virion production (Figure 6A, M4,
lane 3). A less dramatic effect was observed when only
two basic residues on the proposed membrane target-
ing surface were mutated (M5, R32A, R35S; Figure 5A),
which reduced the dominant-negative effect only
slightly (Figure 6A, M5, lane 4). However, the combina-
tion of the M4 and M5 mutations completely reversed
the dominant-negative effect observed for wild-type
GFP-PK-CHMP3(1–150), allowing wild-type levels of vi-
rion production (Figure 6A, M4+5, lane 5). The CHMP3
fusion proteins had no or only a moderate effect on the
overall levels of cell-associated HIV-1 Gag; however,
wild-type CHMP3(1–150), in particular, altered the ratio
of CA to CA-p2, as expected for a late assembly defect
(Figure 6B, lanes 1–5). Of note, each mutant CHMP3 fu-
sion protein was expressed at least as well as the paren-
tal molecule (Figure 6C, lanes 1–5). Cellular distribution
of wild-type GFP-PK-CHMP3(1–150) indicates predom-
inantly plasma membrane and vesicular localization,
while the mutant forms of GFP-PK-CHMP3(1–150) M4
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faces Are Required for the Dominant-Negative Effect of a Truncated
CHMP3 Fusion Protein on HIV-1 Virus Particle Production
(A) HIV-1 particle release upon expression of GFP-PK (control; lanes
1, 6, and 11), wild-type GFP-PK-CHMP3(1–150; lanes 2, 7, and 12),
and GFP-PK-CHMP3(1–150) mutants: M4 (R24S, K25A, R28S),
lane 3; M5 (R32A, R35S), lane 4; M4+5, lane 5; M1 (Y78R, A79E),
lane 8; M1.2 (Y78R, A79E, A82Y), lane 9; M2 (K54S, Q56N, V59E,
V62D, L63D), lane 13; M3 (combination of M1 and M2), lane 10.
HIV-1 Gag proteins were detected by Western blot analysis with
anti-CA serum.
(B) Cellular levels of the HIV Gag proteins Pr55, p41, CA, and CA-P2
upon expression of GFP-PK (control) and GFP-PK-CHMP3(1–150)
mutants as indicated in (A).
(C) Expression levels of GFP-PK (control), wild-type GFP-PK-
CHMP3(1–150), and GFP-PK-CHMP3(1–150) mutants as indicated
in (A) were detected by Western blot using an anti-GFP antibody.and M4+5 show a predominant cytoplasmic localization
(Figure 6D). These results are thus consistent with
a model that implicates an extensive basic surface clus-
ter of CHMP3 that is conserved from yeast to mammals
(residues R24, K25, R28, R32, R35; Figure 5A) in lipid bi-
layer interaction, which is required for CHMP3 protein
function in HIV-1 budding.
The same HIV-1 budding assay was used to evaluate
the dimerization mutants M1, M2, and M3 in the context
of GFP-PK-CHMP(1–150) expression. This showed that
the M1 and M1.2 mutations prevented virus production,
like wild-type GFP-PK-CHMP3(1–150) (Figure 6A, WT,
M1, M1.2, lanes 7–9), while the M2 mutation slightly re-
duced the dominant-negative effect of wild-type GFP-
PK-CHMP3(1–150), allowing some virus production
(Figure 6A, WT and M2, lanes 12 and 13). In contrast,
the double mutant M3 completely reversed the domi-
nant-negative effect of wild-type GFP-PK-CHMP3(1–
150), allowing normal HIV-1 virion production (Figure 6A,
M3, lane 10). These results suggest that changes on the
helical hairpin surface (M2; dimer 2) are slightly more
sensitive to HIV-1 budding inhibition than those within
the M1 (dimer 1) interface; however, our results suggest
that both cooperate to achieve a dominant-negative ef-
fect on HIV-1 budding. The expression of the mutant
GFP-PK-CHMP3(1–150) had no or only a moderate ef-
fect on the overall levels of cell-associated HIV-1 Gag
(Figure 6B, lanes 6–13), and each mutant GFP-PK-
CHMP3(1–150) was expressed at similar levels as wild-
type GFP-PK-CHMP3(1–150) (Figure 6C, lanes 6–13).
Finally, mutations within both dimerization interfaces
altered the cellular localization of GFP-PK-CHMP3(1–
150). All three dimerization mutants, M1, M2, and M3,
showed predominantly cytoplasmic localization as
compared to wild-type CHMP3(1–150) (Figure 6D), im-
plying that the dimer interfaces are required for efficient
plasma membrane localization.
Discussion
CHMP proteins form ESCRT-III complexes and together
with ESCRT-I and -II belong to the class E Vps protein
machinery that has been implicated in MVB biogenesis
and enveloped virus budding (Katzmann et al., 2002;
Morita and Sundquist, 2004). They are targeted to cellu-
lar membranes, where they have been suggested to
form a protein lattice which is required for late steps in
budding (Babst et al., 2002a; Lin et al., 2005; Martin-Ser-
rano et al., 2003; Strack et al., 2003; von Schwedler et al.,
2003). Here we show that wild-type CHMP3 folds into
a monomer and that removal of most of the C-terminal
acidic domain is sufficient to induce dimerization in vitro,
indicating that CHMP3 monomers are in a metastable
conformation. Although we crystallized a truncated
form of CHMP3 that is monomeric in solution, the crystal
structure of CHMP3(9–183) reveals two potential dimer-
ization interfaces from the crystal lattice packing. The di-
mer 1 interface is extensive and typical for a protein
(D) Confocal microscopy images showing plasma membrane asso-
ciation for expression of wild-type GFP-PK-CHMP3(1–150) and
a predominantly cytoplasmic localization for expression of mutants
M1, M2, M3, M4, and M4+5.
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tions (Nooren and Thornton, 2003). This may include
a potential interaction with the C-terminal acidic region
in the monomeric conformation, supporting the hypoth-
esis of CHMP protein activation via the displacement of
the C-terminal acidic tail from the N-terminal core struc-
ture (Lin et al., 2005). The second dimerization interface
present in the crystal lattice (dimer 2) is less extensive.
Our mutagenesis studies show that changes within
both interfaces affect CHMP3 dimerization in vitro. Be-
cause we have no direct evidence for a role of CHMP3
dimers in vivo, we suggest that the interfaces identified
as mediating CHMP3 dimerization in vitro may represent
interaction surfaces for other CHMP proteins in vivo pro-
moting CHMP protein lattice formation on membranes.
Therefore, both interfaces may be used to form either
CHMP3-CHMP2A or even CHMP4/6 and CHMP1/5 sub-
complexes (Babst et al., 2002a; Martin-Serrano et al.,
2003; von Schwedler et al., 2003) that exist already in so-
lution and/or in a CHMP protein lattice on membranes.
The structure suggests that CHMP3 interacts with
membranes via its basic charged surface, which was con-
firmed by mutagenesis studies. Such protein-membrane
interactions via electrostatic forces are favored by the
relative high content of monovalent acidic phospholipids
such as phosphatidylserine (w15%–30%) present in the
inner leaflet of the plasma membrane (McLaughlin,
1989; Murray et al., 1999). In addition, CHMP3 K49, impli-
cated in binding to PtdIns(3,5)P2 (Whitley et al., 2003), is
exposed on this surface, which is further consistent
with this side constituting the membrane interaction sur-
face. The C-terminal ends, which are the target for the
ATPase Vps4 (Fujita et al., 2004; Lin et al., 2005), emanate
from the opposite side of the flat molecule allowing Vps4
access when bound to the membranes, as required for
ESCRT complex disassembly (Babst et al., 1998, 2002a;
Fujita et al., 2003; Lin et al., 2005; Martin-Serrano et al.,
2003; Strack et al., 2003; von Schwedler et al., 2003).
CHMP fusion proteins have been shown to exert
a dominant-negative effect on retrovirus budding (Mar-
tin-Serrano et al., 2003; Strack et al., 2003; von Schwe-
dler et al., 2003). Here we show that a C-terminal trunca-
tion of CHMP3 containing the core four-helical bundle
fused to GFP-PK exerts a strong dominant-negative ef-
fect on HIV-1 budding, a process which requires CHMP3
membrane targeting, as shown by our mutagenesis re-
sults. Similarly, a CHMP3 fusion protein form containing
only the long helical hairpin induces the typical aberrant
class E phenotype and leads to the accumulation of
truncated CHMP3 on endosomal membranes (Whitley
et al., 2003; Lin et al., 2005). This implies that the helical
hairpin, which contains the membrane targeting surface
according to our mutagenesis analyses, is sufficient to
participate in CHMP lattice formation. Because the tar-
get site for Vps4 is either deleted or not accessible in
the CHMP fusion proteins (Scott et al., 2005a, 2005b),
the CHMP proteins are not released from cellular mem-
branes and a dominant-negative effect is detected. A
similar phenotype on HIV-1 budding is observed upon
expression of an inactive Vps4 ATPase (Garrus et al.,
2001; Martin-Serrano et al., 2003; von Schwedler et al.,
2003), which implies that Vps4 is either actively required
for the budding process or the observed phenotype is
a result of a block in CHMP protein recycling.The HIV-1 budding assays presented here revealed
further that both dimer interfaces are important for bud-
ding and cooperate in the inhibitory effect of GFP-PK-
CHMP3(1–150). The relocalization of the dimerization
mutants from the plasma membrane to a predominant
cytoplasmic localization also implies that the interfaces
are required for efficient CHMP3 membrane targeting.
However, because the single mutants (M1 and M2) are
still dominant negative, the amount of M1 and M2 tar-
geted to the membrane may still be sufficient for its
function. Therefore, one possibility is that M1 and M2
can enter a CHMP protein network which cannot be ex-
tended due to the mutations and thus exert a dominant-
negative effect. This last possibility would thus suggest
that the double mutant M3 cannot enter the network and
thus has no effect. Alternatively, the dominant-negative
effect of M1 and M2 may arise from CHMP3 interaction
with soluble subcomplexes.
Both enveloped virus budding and MVB biogenesis
involve budding away from the cytosol, which supplies
all factors required for the process. This poses the ques-
tion as to how the evolving lipid neck structure of a bud
brings the membranes into close enough contact to
overcome the energetic barrier for controlled membrane
fission. The dominant-negative CHMP proteins and in-
active Vps4 both block a late step in virus budding which
is morphologically characterized by fully assembled vi-
ral particles that are connected to the plasma membrane
via a w100–200 A˚ (in diameter) large membrane neck
structure. This suggests that CHMP proteins either
alone or together with Vps4 are essential components
of the membrane fission machinery (Martin-Serrano
et al., 2003; Strack et al., 2003; von Schwedler et al.,
2003).
Our structural and functional analyses of CHMP3 to-
gether with previous studies suggest the following pos-
sible scenarios. First, CHMP monomers become acti-
vated and polymerize potentially via the two
dimerization interfaces over the neck opening in such
a way that the protein lattice connects all membrane
ends. Stepwise disassembly or removal of CHMP pro-
teins from the lattice may then lead to the narrowing of
the neck opening. Although the role of CHMP family
members in virus budding seems to be somewhat re-
dundant (Ward et al., 2005), the overall composition of
a CHMP protein lattice may have a specific effect on
the membrane structure. Second, CHMP protein func-
tion may be coupled to the lipid bilayer content (Matsuo
et al., 2004), which is indirectly supported by the exten-
sive lipid bilayer interaction surface of CHMP3 (w2250
A˚2 per monomer). A number of studies have shown
that lipid bilayers can separate into different lipid phases
in vitro, which in turn can induce spontaneous vesicle
budding (Bacia et al., 2005; Baumgart et al., 2003; Ju-
licher and Lipowsky, 1993; Roux et al., 2005). Therefore,
CHMP-membrane interactions may influence lipid
phase separation processes in vivo. Such a function
may explain the necessity of six different CHMP family
members in yeast or ten in mammals, as each has a dif-
ferent membrane interaction surface. In conclusion, our
structural and functional data suggest that CHMP3 may
be part of the membrane fission machinery that requires
ESCRT-III lattice formation on cellular membranes.
The structure will thus serve as a platform to better
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828understand the process of budding during MVB biogen-
esis and enveloped virus egress from the cell.
Experimental Procedures
Cloning, Protein Expression, and Purification
cDNA fragments derived from human CHMP3 encoding residues 1–
222 (wild-type), 9–183 (CHMP3[9–183]), and 9–164 (CHMP3[9–164])
were subcloned into the expression vector pProExHTb (Invitrogen).
Mutagenesis was performed using standard PCR procedures. The
mutants have the following residues changed: M1, Y78 to R, A79
to E; M1.2, Y78 to R, A79 to E, A82 to Y; M2, K54 to S, Q56 to N,
V59 to E, V62 to D, L63 to D; M3 is a combination of M1 and M2;
M4, R24 to S, K25 to A, R28 to S; M5, R32 to A, R35 to S. Mutations
were introduced into CHMP3(9–164) for bacterial expression and
GFP-PK-CHMP3(1–150) for mammalian expression. All sequences
were confirmed by DNA sequencing. All wild-type and mutant
CHMP proteins were expressed and purified in the same way.
Briefly, protein expression was performed in Escherichia coli strain
BL21 codon plus (Invitrogen) and the incorporation of selenomethio-
nine in the case of CHMP3(9–183) was performed using standard
procedures. The bacterial cell lysate was applied onto an Ni2+ Se-
pharose (Amersham Pharmacia Biotech) column in buffer A (50
mM Tris [pH 8.8], 100 mM NaCl). The column was extensively
washed with buffer A containing 1 M NaCl and 1 M KCl, followed
by a wash step with buffer A containing 1% CHAPS. The column
was subsequently equilibrated with buffer A and CHMP proteins
were eluted by applying an imidazole gradient in buffer A. The His
tag was removed from wild-type and all mutant CHMP3 proteins
by TEV protease cleavage (1:200; w/w, 4ºC, overnight) and the tag
and the TEV protease were removed on an Ni2+ Sepharose column.
Wild-type and mutant CHMP3 proteins were further purified on
a Superdex 75 column in either buffer B (20 mM bicine [pH 9.0],
100 mM NaCl), buffer C (20 mM HEPES [pH 8.5], 100 mM NaCl), or
in the case of selenomethionine-substituted CHMP3(9–183), in
buffer D (20 mM sodium cacodylate [pH 6.5], 100 mM NaCl, 2 mM
b-mercaptoethanol). Chemical crosslinking of wild-type and mutant
CHMP3 was performed at a protein concentration of 0.5 mg/ml in
buffer C using ethylene glycol bis-succinimide at the concentrations
indicated. The reaction was quenched with 100 mM Tris (pH 8.0).
Crystallization, Diffraction Data Collection, and Structure
Solution
CHMP3(9–183) crystals (usually thin plates) were grown at 20ºC by
vapor diffusion by mixing 1 ml of reservoir solution (8%–12% PEG
3350, 200 mM ammonium acetate) and 1 ml CHMP3(9–183) (w10
mg/ml in buffer D). A selenomethionine-substituted crystal was cryo-
protected in the reservoir buffer supplemented with 25% glycerol,
and then flash cooled in liquid nitrogen. A single wavelength anom-
alous dispersion (SAD) data set was collected at 100 K at beamline
ID14-EH4 (European Synchrotron Radiation Facility, Grenoble)
using an inverse beam strategy for collection of 360º at the peak
wavelength of the selenium K edge (wavelength 0.97927 A˚). The
data were processed using the program XDS (CCP4, 1994; Kabsch,
1988). The crystals belong to space group P1 with unit cell dimen-
sions of a = 33.56 A˚, b = 72.53 A˚, c = 89.16 A˚, and a = 68.66º, b =
83.59º, g = 76.69º and diffract to a resolution of 2.8 A˚ (SAD data sta-
tistics: 94.7% completeness; total number of reflections 76,650;
unique number of reflections 35,544; Rmerge = 0.096; Friedel pairs un-
merged). Analysis of Matthews coefficients revealed that there were
two to four possible molecules in the P1 cell. The positions of 22 se-
lenium sites (15 expected per monomer) were found using the pro-
gram SHELXD (Schneider and Sheldrick, 2002). Initial phases were
calculated using SHELXE (Sheldrick, 2002) and eight additional sites
were found by further refinement of the sites with the program
SHARP, yielding good phasing statistics (FOMacen = 0.40; last shell
2.92–2.80 A˚ = 0.25; PPacen = 1.61; last shell 2.92–2.80 A˚ = 0.60) (de
La Fortelle and Bricogne, 1997). The total of 30 sites was validated
with SOLVE (Terwilliger and Berendzen, 1999) and density modifica-
tion was performed with the program RESOLVE (Terwilliger, 2000),
which revealed three noncrystallographic symmetry (NCS) opera-
tors. However, inspection of the solvent boundaries of the electron
density map as well as the distribution of the anomalous peaks sug-
gested the presence of four molecules in the P1 cell. The additionalNCS operator was found using the program PROFESSS (CCP4,
1994) and 4-fold averaging was performed using the program DM
(CCP4, 1994). The resulting electron density map revealed the pres-
ence of helices and the program ARP/wARP (CCP4, 1994) was used
to build 17 short helical fragments as a polyalanine model. Iterative
model building and refinement was done using the programs COOT
(Emsley and Cowtan, 2004), O (Jones et al., 1991), CNS (Brunger
et al., 1998), and REFMAC (CCP4, 1994). Poorly defined regions
such as loop connections and the position of helix 5 were confirmed
by calculating simulated annealing omit maps. The final model con-
tains four monomers (602 residues out of 716): chain A residues 12–
141 and 161–172, chain B residues 9–140 and 161–180, chain C res-
idues 12–98, 102–140, and 161–176, and chain D residues 9–141 and
156–181. One chain per monomer (chains B and D) contains four ex-
tra residues at the N terminus derived from the vector, which make
important crystal contacts between CHMP protein layers. The struc-
ture was refined to an Rfactor of 0.259 (total reflections, 16,944) and
Rfree of 0.301 (5% test set reflections, 903) with an overall average
B factor of 59.7 A˚2 and good stereochemistry (rmsd bond length =
0.017 A˚; rmsd bond angles = 1.51º); 85.6% of the residues are in
most favored and 13.5% are in additionally allowed regions of
a Ramachandran plot according to analysis with the program
PROCHECK (CCP4, 1994). The coordinates have been deposited
in the Protein Data Bank (PDB code: 2GD5).
Structure Analysis
Figures were generated with the programs ESPript (Gouet et al.,
1999), PyMOL (http://www.pymol.org), and GRASP (Nicholls et al.,
1991). Sequences were aligned using Clustalx (Thompson et al., 1997).
Secondary structure elements were assigned using the program
DSSP (Kabsch and Sander, 1983).
Analysis of HIV-1 Virus Production
A fragment encoding CHMP3 residues 1–150 was amplified by PCR
and fused to a GFP-pyruvate kinase chimera (GFP-PK) provided by
Warner Greene (University of California, San Francisco). To deter-
mine the effect of GFP-PK-CHMP3(1–150) on virus production,
293T cells (1.5 3 106) were seeded into T25 flasks and transfected
24 hr later using a calcium phosphate precipitation technique. The
cultures were cotransfected with 1.5 mg of the full-length HIV-1 pro-
viral construct HXBH10 and with 0.5 mg of either GFP-PK or wild-
type and mutant versions of GFP-PK-CHMP3(1–150). Twenty-four
hours posttransfection, virions released into the culture medium
were pelleted through sucrose. HIV-1 Gag proteins in virion and
cell lysates were detected by Western blotting with a rabbit anti-
HIV CA antiserum (Advanced Biotechnologies), and CHMP3 fusion
proteins were detected with an anti-GFP monoclonal antibody (Mo-
lecular Probes). Expression of wild-type GFP-PK-CHMP3(1–150),
and that of all mutants, was analyzed by confocal microscopy
24 hr posttransfection in 293T cells.
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